Jelmyto was UroGen Pharma’s largest product and service line in fiscal 2025, bringing in $93.99M of $109.79M (86%).
| Product and Service | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|
| Jelmyto | $64.36M | $82.71M | $90.40M | $93.99M | ||
| Zusduri | — | — | — | $15.80M | ||
| Total | $64.36M | $82.71M | $90.40M | $109.79M |
UroGen Pharma brought in $109.79M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. UroGen Pharma regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $90.40M. Jelmyto was the largest at $93.99M (85.6%), ahead of Zusduri at $15.80M (14.4%).
UroGen Pharma began breaking out Zusduri in fiscal 2025, when it brought in $15.80M.
UroGen Pharma (URGN) reports its revenue by product and service. In fiscal 2025, Jelmyto was its largest product and service line, bringing in $93.99M (85.6% of the total), followed by Zusduri at $15.80M (14.4%).
Jelmyto was UroGen Pharma's largest product and service line in fiscal 2025, bringing in $93.99M, or 85.6% of the $109.79M total across its two product and service lines.
Every figure comes from UroGen Pharma's annual financial filings, as reported. Each line keeps the name UroGen Pharma gives it, and years follow its fiscal calendar.
UroGen Pharma's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.